BeiGene PD-1 Tislelizumab Shows Survival Benefit In Esophageal Cancer

The PD-1 inhibitor, approved in China, will be a late entry to the US and European markets, where it is partnered with Novartis, but is supported by a broad clinical trial program.

Esophageal Cancer vector — BeiGene's PD-1 inhibitor improved overall survival in esophageal cancer • Source: Shutterstock

BeiGene, Ltd. has notched another potential indication for the PD-1 inhibitor tislelizumab, this time in advanced unresectable or metastatic esophageal squamous cell carcinoma. Tislelizumab is already approved in China and is targeted for global expansion under a development and commercialization deal with Novartis AG.

"We're in discussions with health authorities globally and expecting to submit the first filing of tislelizumab outside of China this year," the company said. Novartis said the specific filing plans are yet to be determined

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

BioNTech Aims To Diversify BNT323 Manufacturing As Filing Nears

05 May 2025

• By Alaric DeArment

The company plans to expand manufacturing of the HER2-targeting ADC beyond China and plans to file for US FDA approval in 2025.

In Brief: Genmab To Seek FDA Nod For Epkinly In Lymphoma

05 May 2025

• By Sushmita Panda

Genmab will submit an sBLA for Epkinly in R/R follicular lymphoma in H1 2025, backed by positive Phase III data.

Merck & Co. CMO Barr On Breaking Into Immunology And Ophthalmology

02 May 2025

• By Jessica Merrill

Chief medical officer Eliav Barr discussed Merck’s investment in new therapeutic areas and business development in an interview with Scrip.

Zai’s R&D Head Touts ‘Beauty’ Of Novel Internal Assets

01 May 2025

• By Dexter Jie Yan

Two potentially first-in-class molecules signify Zai Lab’s renewed drive for the in-house discovery of drugs that it requires “to be innovative, differentiated and to have the potential to make a big difference for patients,” its global R&D head tells Scrip.